Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteogenesis imperfecta: practical treatment guidelines.

F Antoniazzi1, M Mottes, P Fraschini

  • 1Dipartimento Materno-Infantile e di Biologia-Genetica, Università degli Studi di Verona, Italy. francoa@borgoroma.univr.it

Paediatric Drugs
|December 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of genetic investigation in the diagnosis of short stature in a cohort of Italian children.

Journal of endocrinological investigation·2023
Same author

The clinical management of children with achondroplasia in Italy: results of clinician and parent/caregiver surveys.

Journal of endocrinological investigation·2023
Same author

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic.

Orphanet journal of rare diseases·2020
Same author

Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.

Journal of endocrinological investigation·2020
Same author

Increased Gene Expression of RUNX2 and SOX9 in Mesenchymal Circulating Progenitors Is Associated with Autophagy during Physical Activity.

Oxidative medicine and cellular longevity·2019
Same author

X-linked hypophosphatemic rickets: an Italian experts' opinion survey.

Italian journal of pediatrics·2019
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
Same journal

Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

Paediatric drugs·2026
See all related articles

Osteogenesis imperfecta (OI) is a bone fragility disorder. Treatment includes physical therapy, surgery, and medications like bisphosphonates, which improve bone density and reduce fractures.

Area of Science:

  • Genetics and Molecular Biology
  • Orthopedics
  • Pediatrics

Background:

  • Osteogenesis imperfecta (OI) is an inherited connective tissue disorder characterized by bone fragility due to defects in collagen synthesis.
  • Clinical presentation of OI varies significantly, impacting prognosis, mobility, and autonomy.

Purpose of the Study:

  • To outline the diagnosis, treatment, and management strategies for Osteogenesis Imperfecta.
  • To review current and emerging therapeutic interventions for OI.

Main Methods:

  • Multidisciplinary team approach for diagnosis and tailored treatment.
  • Review of nonsurgical (physical therapy, bracing), surgical (intramedullary rodding), and pharmacological interventions (bisphosphonates, growth hormone).

Main Results:

Related Experiment Videos

  • Intramedullary telescopic rodding is effective in preventing/correcting long bone fractures and improving mobility.
  • Bisphosphonates have shown significant benefits in children with severe OI, increasing bone mineral density and reducing fracture rates and pain.
  • Growth hormone may benefit patients with moderate OI, positively influencing bone turnover and height velocity.

Conclusions:

  • Current treatments for OI are symptomatic, focusing on improving bone strength and reducing fractures.
  • Bisphosphonates have markedly improved morbidity in OI patients, though further controlled studies are needed.
  • Future genetic therapies hold promise for correcting the underlying molecular defect in OI.